For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as “A Solution in Search of a Problem.”
In his article, Patent Docs’ Kevin Noonan explains the motivations to amend the way in which the Foood and Drug Administration approves biologic drugs. He argues that one of the justifications for the proposed legal changes — that it addresses a challenge faced by biosimilar applicants in identifying patents covering drugs is weakened because “…these concerns fly in the face of available outlets (for example, www.drugpatentwatch.com) that has this information readily available.”
But these concerns fly in the face of available outlets (for example, www.drugpatentwatch.com) that has this information readily available.
For more on follow-on biologics, see our blog posts at Predicting Patent Litigation Outcomes for Biosimilars and Exploring Biosimilars as a Drug Patent Strategy, and our deep database of biopharmaceutical business intelligence at www.DrugPatentWatch.com .
Copyright © DrugPatentWatch. Originally published at DrugPatentWatch in the news: The Biologic Patent Transparency Act.